← Back to patent-cliff list
非诺贝特/辛伐他汀
Tier C — Watch / tradeFenofibrate/Simvastatin
Mylan Nv
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PPAR、HMGCR
Brand：Cholib
Indications (approved)：血脂障碍
Regional status
US
-
EU
批准上市
2013-08-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fenofibrate/Simvastatin?
Approved indications include: 血脂障碍.
When does the Fenofibrate/Simvastatin patent expire?
No public expiry year is available for Fenofibrate/Simvastatin yet; this page updates once verified.
How do I get a quote for Fenofibrate/Simvastatin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24